Adicet Bio raises $51 mln
Adicet Bio Inc. said Wednesday it closed a $51 million Series A round led OrbiMed. Novartis Venture Fund and Pontifax also invested. Menlo Park, California-based Adicet is a pre-clinical stage biotechnology company that designs and develops immunotherapies for cancer and other disease indications.
27 January 2016•3 mins read
